Abstract

SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM⁺IgG⁺, 9.0% IgM⁺IgG⁻, and 5.0% IgM⁻IgG⁺). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM⁺IgG⁻. These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection.

中文翻译：

---

马萨诸塞州切尔西的抗 SARS-CoV-2 抗体的高血清阳性率。

摘要

SARS-CoV-2 抗体检测可以定量确定疾病流行情况，这在高风险社区尤为重要。我们通过 BioMedomics SARS-CoV-2 结合 IgM-IgG 即时横向流动免疫测定法，对 200 名目前无症状的切尔西（马萨诸塞州 COVID-19 疾病的中心）居民进行了匿名便利抽样。血清阳性率为 31.5%（17.5% IgM ⁺ IgG ⁺、9.0% IgM ⁺ IgG ^-和 5.0% IgM ^- IgG ⁺）。在 200 名参与者中，50.5% 的人报告在前 4 周内没有症状，其中 24.8% (25/101) 为血清阳性，其中 60% 为 IgM ⁺ IgG ^-. 这些数据是迄今为止观察到的最高血清阳性率，并突出了无症状感染的重大负担。